Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
It received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell carcinoma, epithelial ovarian cancer and carcinoma of the cervix
Systemic inflammation is a key driver of mortality in SARS-CoV-2 in cancer patients and biomarkers of inflamation may be used to identify patients at increased risk
Innovative risk-assessment tool measures the patient’s local immune response to the tumour
All of the pembrolizumab regimens were safe in patients with metastatic castration-resistant prostate cancer
KEYNOTE-426 data from patients enrolled in Eastern Asia is consistent with that of the overall population
Safety has already been demonstrated for sintilimab, a monoclonal antibody targeting the PD-1, plus a bevacizumab biosimilar as first-line treatment for advanced hepatocellular carcinoma
Improved outcomes following first-line CS1001/chemotherapy were observed in Chinese patients with both squamous and non-squamous histology
Efficacy of the irreversible pan-HER tyrosine kinase inhibitor, neratinib, consistent with the results in the overall NALA population
Findings at 4-year follow-up in East Asian patients with advanced HR-positive, HER2-negative breast cancer are consistent with those in the overall MONARCH 2 study population
The most widely used therapies and subsequent outcomes were identified with the aim of informing T-cell lymphoma treatment
The Japan subset showed similar progression-free survival to the overall PAOLA-1 population
Data from the subgroup of patients from Asia-Pacific with pretreated triple negative breast cancer were similar to that observed in overall KEYNOTE-119 study population
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
